The reason for the exclusion is the existence of Investigational New Drug (IND) applications on CBD by English company GW Pharmaceuticals, which is developing two drugs called Sativex and Epidiolex featuring the molecule as an active ingredient. Sativex is aimed at quelling the spasticity associated with multiple sclerosis, whereas Epidiolex is meant to address certain intractable forms of childhood epilepsy.